Monoclonal antibody SM-3

Drug Profile

Monoclonal antibody SM-3

Alternative Names: SM-3

Latest Information Update: 25 Jun 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imperial Cancer Research Technology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Polycythaemia vera

Most Recent Events

  • 19 Sep 2001 No-Development-Reported for Polycythaemia vera in United Kingdom (Unknown route)
  • 14 Jul 1998 No-Development-Reported for Cancer in Germany (Unknown route)
  • 14 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top